Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Lessened by Sphera Funds Management LTD.

Sphera Funds Management LTD. trimmed its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 22.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 98,921 shares of the biotechnology company's stock after selling 27,925 shares during the period. Sarepta Therapeutics accounts for about 2.2% of Sphera Funds Management LTD.'s investment portfolio, making the stock its 10th largest position. Sphera Funds Management LTD. owned about 0.10% of Sarepta Therapeutics worth $12,028,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Manchester Capital Management LLC grew its stake in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after buying an additional 156 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter worth about $36,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after buying an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after buying an additional 216 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on SRPT. Scotiabank lowered their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a report on Thursday, March 20th. The Goldman Sachs Group lowered their price target on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Cantor Fitzgerald lowered their price target on shares of Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. UBS Group lowered their price target on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, Wells Fargo & Company lowered their price target on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $124.36.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Trading Up 4.1%

SRPT stock traded up $1.51 during midday trading on Monday, reaching $37.94. 3,646,314 shares of the company's stock traded hands, compared to its average volume of 1,720,171. The company has a market capitalization of $3.73 billion, a P/E ratio of 30.35 and a beta of 0.85. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a fifty-two week low of $34.10 and a fifty-two week high of $173.25. The business has a 50-day moving average price of $60.11 and a two-hundred day moving average price of $97.18.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company's quarterly revenue was up 80.2% on a year-over-year basis. During the same period last year, the firm earned $0.73 earnings per share. Equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.